Sanara MedTech (SMTI) Q2 2024 earnings summary

Executive summary

• Achieved eleventh consecutive record revenue quarter with $20.2 million in Q2 2024, up 28% year-over-year, driven by increased soft tissue repair product sales and expanded distribution.

• Net loss of $3.5 million in Q2 2024, compared to $1.9 million in Q2 2023, primarily due to higher SG&A, executive separation, and acquisition costs.

• Adjusted EBITDA improved to $0.6 million in Q2 2024 from $(0.3) million in Q2 2023, reflecting improved core business performance.

• Continued investment in Tissue Health Plus (THP), with $4–5 million planned for H2 2024 and commercial launch expected in H2 2025.

• Expanded product reach to over 1,100 facilities in 34 states and 4,000+ hospitals/ASCs, and strengthened management with new executive appointments.

Financial highlights

• Q2 2024 revenue: $20.2 million, up from $15.8 million in Q2 2023 (28% increase); gross profit for Q2 2024 was $18.2 million, with gross margin rising to 90%.

• SG&A expenses rose to $19 million from $13.8 million year-over-year, including $0.9 million in executive separation and $0.4 million in acquisition costs.

• R&D expenses decreased to $1 million from $1.2 million, mainly due to lower costs in the THP segment.

• Interest expense was $0.6 million, related to a new term loan; depreciation and amortization increased to $1.1 million.

• Cash balance at quarter-end: $6.2 million, up from $5.1 million at year-end 2023.

Outlook and guidance

• THP program commercial launch planned for H2 2025, with significant investment in technology and infrastructure in H2 2024.

• Management anticipates synergistic M&A and partnership opportunities as key growth drivers.

• Management expects cash on hand, operating cash flow, and available CRG Term Loan proceeds to fund operations and growth for at least the next 12 months.

• Growth initiatives for 2024 and 2025 to be supported by the new term loan.

• Continued focus on expanding distribution network and market penetration.